Payment overview · 2025
General Payments
$1,124.22
44 reported records · 20 companies
Healthcare provider profile · identity verified
Stephen M Canowitz, MD
Allopathic & Osteopathic Physicians|Pediatrics · GAHANNA, OH · NPI 1174573224
Verified facts
What the public records show
CMS Open Payments records show Stephen M Canowitz, MD received $1,124.22 in general payments during 2025 across 44 reported records.
Lilly USA, LLC accounted for 15.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 28 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rexulti.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 50 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 1014 claims for Eliquis by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Fiasp as an associated drug or biological on 15 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Fiasp by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1014 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $176.89 | 15.7% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $176.02 | 15.7% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $112.46 | 10.0% | 6 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $92.50 | 8.2% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $77.33 | 6.9% | 4 | 2025 |
| Smith+Nephew, Inc. | Unresolved — no canonical attribution shown | $70.57 | 6.3% | 2 | 2025 |
| Circassia Inc. | Unresolved — no canonical attribution shown | $68.70 | 6.1% | 2 | 2025 |
| ETS Wound Care LLC | Unresolved — no canonical attribution shown | $46.32 | 4.1% | 2 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $37.53 | 3.3% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $37.46 | 3.3% | 2 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $33.11 | 3.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $31.99 | 2.9% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $25.08 | 2.2% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $24.60 | 2.2% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $24.22 | 2.1% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$22.41 | 2.0% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $19.38 | 1.7% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $18.09 | 1.6% | 1 | 2025 |
| Integra LifeSciences Corporation | Unresolved — no canonical attribution shown | $16.92 | 1.5% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $12.64 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,124.22 | 44 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $176.89 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $138.64 | 2 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $92.50 | 5 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $77.33 | 4 | 2025 |
Source payment records
|
|||||
| NIOX Normalized: niox |
Device | Circassia Inc. | $68.70 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $60.61 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $51.85 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $51.85 | 3 | 2025 |
Source payment records
|
|||||
| MIRRAGEN ADVANCED WOUND MATRIX Normalized: mirragen advanced wound matrix |
Device | ETS Wound Care LLC | $46.32 | 2 | 2025 |
Source payment records
|
|||||
| ALLEVYN HEEL 10.5CM X 13.5CM CTN 5 Normalized: allevyn heel 10 5cm x 13 5cm ctn 5 |
Device | Smith+Nephew, Inc. | $42.43 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $37.53 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $37.46 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $37.38 | 2 | 2025 |
Source payment records
|
|||||
| Vyrsa V1 Normalized: vyrsa v1 |
Device | Globus Medical, Inc. | $33.11 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $31.99 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $31.99 | 2 | 2025 |
Source payment records
|
|||||
| STRAVIX Normalized: stravix |
Biological | Smith+Nephew, Inc. | $28.14 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $25.08 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $24.60 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $24.22 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $22.41 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $18.09 | 1 | 2025 |
Source payment records
|
|||||
| Integra Normalized: integra |
Device | Integra LifeSciences Corporation | $16.92 | 1 | 2025 |
Source payment records
|
|||||
| Integra Dermal Regeneration Template Normalized: integra dermal regeneration template |
Device | Integra LifeSciences Corporation | $16.92 | 1 | 2025 |
Source payment records
|
|||||
| PRIMATRIX Normalized: primatrix |
Device | Integra LifeSciences Corporation | $16.92 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $12.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1014 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 55 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
50 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1014 | 181 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
110 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
120 | 21 |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Fiasp open payments reported associated product |
CMS Open Payments — General Payments 15 supporting records · 15 recipient NPIs · example record 1188262936 |
Fiasp · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
55 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
25 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1014 | 181 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 2395 | 488 |
| Amlodipine Besylate | Amlodipine Besylate | 1087 | 235 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1079 | 233 |
| Eliquis | Apixaban | 1014 | 181 |
| Furosemide | Furosemide | 956 | 218 |
| Lisinopril | Lisinopril | 832 | 163 |
| Pantoprazole Sodium | Pantoprazole Sodium | 830 | 176 |
| Gabapentin | Gabapentin | 828 | 180 |
| Sertraline Hcl | Sertraline Hcl | 777 | 118 |
| Metoprolol Succinate | Metoprolol Succinate | 675 | 156 |
| Losartan Potassium | Losartan Potassium | 660 | 156 |
| Potassium Chloride | Potassium Chloride | 632 | 147 |
| Metoprolol Tartrate | Metoprolol Tartrate | 609 | 130 |
| Trazodone Hcl | Trazodone Hcl | 605 | 131 |
| Mirtazapine | Mirtazapine | 579 | 123 |
| Metformin Hcl | Metformin Hcl | 562 | 115 |
| Donepezil Hcl | Donepezil Hcl | 515 | 85 |
| Buspirone Hcl | Buspirone Hcl | 511 | 95 |
| Omeprazole | Omeprazole | 502 | 138 |
| Carvedilol | Carvedilol | 491 | 107 |
| Tamsulosin Hcl | Tamsulosin Hcl | 435 | 102 |
| Levetiracetam | Levetiracetam | 377 | 61 |
| Memantine Hcl | Memantine Hcl | 352 | 60 |
| Baclofen | Baclofen | 334 | 47 |
| Clopidogrel | Clopidogrel Bisulfate | 316 | 87 |
| Famotidine | Famotidine | 308 | 59 |
| Duloxetine Hcl | Duloxetine Hcl | 307 | 70 |
| Quetiapine Fumarate | Quetiapine Fumarate | 300 | 55 |
| Allopurinol | Allopurinol | 294 | 54 |
| Xarelto | Rivaroxaban | 293 | 53 |
| Simvastatin | Simvastatin | 280 | 63 |
| Hydrochlorothiazide | Hydrochlorothiazide | 279 | 53 |
| Warfarin Sodium | Warfarin Sodium | 276 | 31 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 271 | 62 |
| Escitalopram Oxalate | Escitalopram Oxalate | 270 | 52 |
| Citalopram Hbr | Citalopram Hydrobromide | 264 | 52 |
| Divalproex Sodium | Divalproex Sodium | 260 | 46 |
| Finasteride | Finasteride | 253 | 57 |
| Fluoxetine Hcl | Fluoxetine Hcl | 229 | 43 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 201 | 30 |
| Olanzapine | Olanzapine | 189 | 26 |
| Spironolactone | Spironolactone | 184 | 44 |
| Oxybutynin Chloride | Oxybutynin Chloride | 181 | 31 |
| Torsemide | Torsemide | 175 | 35 |
| Midodrine Hcl | Midodrine Hcl | 171 | 41 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 162 | 74 |
| Hydralazine Hcl | Hydralazine Hcl | 161 | 35 |
| Methenamine Hippurate | Methenamine Hippurate | 160 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 158 | 85 |
| Lactulose | Lactulose | 153 | 19 |
| Montelukast Sodium | Montelukast Sodium | 150 | 30 |
| Amiodarone Hcl | Amiodarone Hcl | 149 | 38 |
| Humalog Kwikpen U-100 | Insulin Lispro | 149 | 32 |
| Prednisone | Prednisone | 148 | 55 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 143 | 80 |
| Pravastatin Sodium | Pravastatin Sodium | 143 | 29 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 141 | 33 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 132 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 132 | 42 |
| Ropinirole Hcl | Ropinirole Hcl | 129 | 21 |
| Atenolol | Atenolol | 128 | 23 |
| Meloxicam | Meloxicam | 128 | 30 |
| Cephalexin | Cephalexin | 126 | 73 |
| Ezetimibe | Ezetimibe | 124 | 37 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 122 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 120 | 24 |
| Trulicity | Dulaglutide | 120 | 21 |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 116 | 18 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 113 | 40 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 112 | 30 |
| Doxycycline Hyclate | Doxycycline Hyclate | 111 | 65 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 110 | 25 |
| Jardiance | Empagliflozin | 110 | 20 |
| Myrbetriq | Mirabegron | 109 | 17 |
| Januvia | Sitagliptin Phosphate | 107 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 105 | 53 |
| Bupropion Xl | Bupropion Hcl | 104 | 27 |
| Doxazosin Mesylate | Doxazosin Mesylate | 103 | 17 |
| Nifedipine Er | Nifedipine | 103 | 27 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 98 | 64 |
| Diclofenac Sodium | Diclofenac Sodium | 98 | 40 |
| Ondansetron Odt | Ondansetron | 98 | 51 |
| Alendronate Sodium | Alendronate Sodium | 95 | 24 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 93 | 30 |
| Lansoprazole | Lansoprazole | 89 | 12 |
| Latanoprost | Latanoprost | 88 | 30 |
| Tizanidine Hcl | Tizanidine Hcl | 85 | 22 |
| Clonidine Hcl | Clonidine Hcl | 84 | 17 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 82 | 18 |
| Vancomycin Hcl | Vancomycin Hcl | 80 | 16 |
| Sodium Chloride | 0.9 % Sodium Chloride | 79 | 23 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 77 | 53 |
| Glimepiride | Glimepiride | 73 | 26 |
| Pioglitazone Hcl | Pioglitazone Hcl | 72 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 71 | 53 |
| Lamotrigine | Lamotrigine | 71 | 18 |
| Entresto | Sacubitril/Valsartan | 70 | 11 |
| Levofloxacin | Levofloxacin | 70 | 53 |
| Tradjenta | Linagliptin | 70 | suppressed |
| Lovastatin | Lovastatin | 69 | 14 |
| Scopolamine | Scopolamine | 69 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 69 | 15 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 66 | 13 |
| Acetic Acid | Acetic Acid | 64 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 64 | 23 |
| Propranolol Hcl | Propranolol Hcl | 63 | 14 |
| Fluconazole | Fluconazole | 61 | 29 |
| Incruse Ellipta | Umeclidinium Bromide | 60 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 60 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 59 | 23 |
| Novolog Flexpen | Insulin Aspart | 59 | 17 |
| Metformin Hcl Er | Metformin Hcl | 58 | 21 |
| Nystatin | Nystatin | 58 | 40 |
| Primidone | Primidone | 57 | 11 |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 56 | 13 |
| Oxcarbazepine | Oxcarbazepine | 56 | suppressed |
| Ozempic | Semaglutide | 55 | 14 |
| Trimethoprim | Trimethoprim | 55 | suppressed |
| Meropenem | Meropenem | 54 | 11 |
| Methocarbamol | Methocarbamol | 54 | 24 |
| Metoclopramide Hcl | Metoclopramide Hcl | 54 | suppressed |
| Humalog | Insulin Lispro | 53 | 15 |
| Klayesta | Nystatin | 53 | 28 |
| Albuterol Sulfate | Albuterol Sulfate | 51 | 32 |
| Ceftriaxone | Ceftriaxone Sodium | 50 | 19 |
| Creon | Lipase/Protease/Amylase | 50 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 50 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 49 | 30 |
| Diltiazem Hcl | Diltiazem Hcl | 49 | 11 |
| Cimetidine | Cimetidine | 48 | suppressed |
| Gemtesa | Vibegron | 48 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 47 | 39 |
| Ketoconazole | Ketoconazole | 46 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 46 | 12 |
| Ranolazine Er | Ranolazine | 46 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 25 |
| Celecoxib | Celecoxib | 45 | 11 |
| Calcitriol | Calcitriol | 44 | 14 |
| Tramadol Hcl | Tramadol Hcl | 44 | 16 |
| Fenofibrate | Fenofibrate Nanocrystallized | 43 | suppressed |
| Acyclovir | Acyclovir | 42 | suppressed |
| Admelog | Insulin Lispro | 42 | 12 |
| Carbamazepine | Carbamazepine | 42 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 42 | 16 |
| Terazosin Hcl | Terazosin Hcl | 42 | suppressed |
| Amoxicillin | Amoxicillin | 41 | 20 |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 41 | 13 |
| Benztropine Mesylate | Benztropine Mesylate | 40 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 40 | suppressed |
| Ibuprofen | Ibuprofen | 39 | 12 |
| Labetalol Hcl | Labetalol Hcl | 39 | suppressed |
| Lorazepam | Lorazepam | 38 | 24 |
| Azithromycin | Azithromycin | 37 | 26 |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | suppressed |
| Novolin R | Insulin Regular, Human | 37 | suppressed |
| Estradiol | Estradiol | 36 | 12 |
| Tresiba Flextouch U-100 | Insulin Degludec | 36 | suppressed |
| Anastrozole | Anastrozole | 35 | suppressed |
| Ampicillin-Sulbactam | Ampicillin Sod/Sulbactam Sod | 34 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 34 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 34 | 12 |
| Nortriptyline Hcl | Nortriptyline Hcl | 34 | suppressed |
| Aripiprazole | Aripiprazole | 33 | 11 |
| Dexamethasone | Dexamethasone | 33 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 33 | 26 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 33 | 13 |
| Insulin Lispro | Insulin Lispro | 32 | 14 |
| Propafenone Hcl Er | Propafenone Hcl | 32 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 31 | suppressed |
| Novolog | Insulin Aspart | 31 | 14 |
| Sodium Bicarbonate | Sodium Bicarbonate | 31 | suppressed |
| Calcium Acetate | Calcium Acetate | 30 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 30 | suppressed |
| Glipizide Er | Glipizide | 30 | suppressed |
| Admelog Solostar | Insulin Lispro | 29 | 12 |
| Bethanechol Chloride | Bethanechol Chloride | 29 | suppressed |
| Dantrolene Sodium | Dantrolene Sodium | 29 | suppressed |
| Loperamide | Loperamide Hcl | 29 | 14 |
| Prednisolone Acetate | Prednisolone Acetate | 29 | 11 |
| Propafenone Hcl | Propafenone Hcl | 29 | suppressed |
| Risperidone | Risperidone | 29 | 12 |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 28 | 17 |
| Cefepime Hcl | Cefepime Hcl | 28 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 28 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 28 | 13 |
| Haloperidol | Haloperidol | 28 | suppressed |
| Lokelma | Sodium Zirconium Cyclosilicate | 28 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 13 |
| Pentoxifylline | Pentoxifylline | 28 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 28 | suppressed |
| Bumetanide | Bumetanide | 27 | suppressed |
| Glipizide | Glipizide | 27 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 27 | 15 |
| Lidocaine | Lidocaine | 27 | 12 |
| Methotrexate | Methotrexate Sodium | 27 | suppressed |
| Atropine Sulfate | Atropine Sulfate | 26 | 17 |
| Darifenacin Er | Darifenacin Hydrobromide | 26 | suppressed |
| Lidocaine Hcl | Lidocaine Hcl | 26 | 19 |
| Nyamyc | Nystatin | 26 | 14 |
| Restasis | Cyclosporine | 26 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 25 | 23 |
| Digoxin | Digoxin | 25 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 25 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 13 |
| Raloxifene Hcl | Raloxifene Hcl | 25 | suppressed |
| Repatha Syringe | Evolocumab | 25 | suppressed |
| Sucralfate | Sucralfate | 25 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 24 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 24 | suppressed |
| Klor-Con M20 | Potassium Chloride | 24 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 24 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 24 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 23 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 23 | suppressed |
| Linzess | Linaclotide | 23 | suppressed |
| Methylprednisolone | Methylprednisolone | 23 | 18 |
| Topiramate | Topiramate | 23 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 23 | suppressed |
| Budesonide | Budesonide | 22 | suppressed |
| Dulera | Mometasone/Formoterol | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 22 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 22 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Cefdinir | Cefdinir | 21 | 17 |
| Hydrocortisone | Hydrocortisone | 21 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 20 | suppressed |
| Clonazepam | Clonazepam | 20 | suppressed |
| Galantamine Hbr | Galantamine Hbr | 20 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 20 | suppressed |
| Timolol Maleate | Timolol Maleate | 20 | suppressed |
| Chlorthalidone | Chlorthalidone | 19 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 19 | suppressed |
| Fenofibrate | Fenofibrate | 19 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 19 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 19 | 14 |
| Daptomycin | Daptomycin | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Dorzolamide Hcl | Dorzolamide Hcl | 18 | suppressed |
| Levemir Flexpen | Insulin Detemir | 18 | suppressed |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Xifaxan | Rifaximin | 18 | suppressed |
| Zonisade | Zonisamide | 18 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 17 | suppressed |
| Clonidine | Clonidine | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Amantadine | Amantadine Hcl | 16 | suppressed |
| Ciclopirox | Ciclopirox Olamine | 16 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 16 | suppressed |
| Ingrezza | Valbenazine Tosylate | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 15 | suppressed |
| Cyclosporine | Cyclosporine | 15 | suppressed |
| Fiasp | Insulin Aspart (Niacinamide) | 15 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 15 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 15 | suppressed |
| Haloperidol Lactate | Haloperidol Lactate | 15 | 12 |
| Levalbuterol Hcl | Levalbuterol Hcl | 15 | suppressed |
| Levemir | Insulin Detemir | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Prazosin Hcl | Prazosin Hcl | 15 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 15 | suppressed |
| Vancomycin | Vancomycin Hcl In 5 % Dextrose | 15 | suppressed |
| Zosyn | Piperacillin-Tazo-Dextrose,iso | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Carbamazepine Er | Carbamazepine | 14 | suppressed |
| Heparin Sodium | Heparin Sodium,porcine | 14 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 14 | suppressed |
| Rexulti | Brexpiprazole | 14 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 13 | suppressed |
| Brimonidine Tartrate-Timolol | Brimonidine Tartrate/Timolol | 13 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 13 | suppressed |
| Cequr Simplicity | Bolus Insulin Pump, 200 Unit | 13 | suppressed |
| Clomipramine Hcl | Clomipramine Hcl | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Ertapenem | Ertapenem Sodium | 13 | suppressed |
| Fluphenazine Hcl | Fluphenazine Hcl | 13 | suppressed |
| Formoterol Fumarate | Formoterol Fumarate | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Hydroxyurea | Hydroxyurea | 13 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 13 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 13 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 13 | suppressed |
| Phenelzine Sulfate | Phenelzine Sulfate | 13 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 13 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 12 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Diltiazem 24hr Er (La) | Diltiazem Hcl | 12 | suppressed |
| Galantamine Er | Galantamine Hbr | 12 | suppressed |
| Olanzapine Odt | Olanzapine | 12 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 12 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 12 | suppressed |
| Ursodiol | Ursodiol | 12 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | 11 |
| Riluzole | Riluzole | 11 | suppressed |
| Trospium Chloride | Trospium Chloride | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,124.22 · 44 records | Lilly USA, LLC | ALLEVYN HEEL 10.5CM X 13.5CM CTN 5, AUSTEDO XR, Auvelity, CAMZYOS, CAPLYTA, Cologuard Collection Kit, ELIQUIS, INCEPTIV, Integra, Integra Dermal Regeneration Template, JOURNAVX, KISUNLA, KRYSTEXXA, MIRRAGEN ADVANCED WOUND MATRIX, NIOX, NUPLAZID, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, PRIMATRIX, REPATHA, REXULTI, Rybelsus, STRAVIX, VRAYLAR, Vyrsa V1, Wegovy | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error